Although human platelets secrete less HGF than rodents [72], TPO receptor agonists stabilize liver functions and reduce liver fibrosis in patients with liver cirrhosis, HCV infection and CLD [73,74]. This evidence concerns the gene HGF and Hepatic fibrosis.